What is PacGenomics?
PacGenomics operates as an advanced clinical laboratory, specializing in a comprehensive suite of molecular diagnostic services. Their offerings encompass infectious disease testing, clinical toxicology, advanced sequencing services, DNA identity testing, and preimplantation genetic testing. By leveraging sophisticated technologies such as Next-Generation Sequencing and Liquid Chromatography-Mass Spectrometry, PacGenomics delivers precise and detailed analyses to healthcare providers and patients alike. The company's commitment to high standards of quality control and data integrity is maintained by a team of highly skilled laboratory professionals, enabling them to support diverse healthcare needs from paternity verification to reproductive genetic insights, thereby empowering precision medicine.
How much funding has PacGenomics raised?
PacGenomics has raised a total of $4.7M across 3 funding rounds:
Private Equity
$1.5M
Private Equity
$3M
Debt
$150K
Private Equity (2013): $1.5M, investors not publicly disclosed
Private Equity (2014): $3M, investors not publicly disclosed
Debt (2020): $150K supported by PPP
Key Investors in PacGenomics
PPP
Public-Private Partnership
What's next for PacGenomics?
The recent major strategic investment positions PacGenomics for significant expansion and technological advancement. This capital infusion is expected to fuel further development of their diagnostic platforms, enhance service offerings, and potentially broaden their market reach. As an enterprise-level funding context, this suggests a focus on scaling operations, optimizing laboratory workflows, and solidifying their competitive edge in the rapidly evolving field of molecular diagnostics. PacGenomics is poised to further its mission of providing cutting-edge solutions for healthcare providers and improving patient outcomes through advanced genetic and molecular testing.
See full PacGenomics company page
